See more : Wi2Wi Corporation (ISEYF) Income Statement Analysis – Financial Results
Complete financial analysis of Cybertrust Japan Co., Ltd. (4498.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cybertrust Japan Co., Ltd., a leading company in the Information Technology Services industry within the Technology sector.
You may be interested
- Huazhang Technology Holding Limited (1673.HK) Income Statement Analysis – Financial Results
- Apollo Global Management, Inc. (AAM-PA) Income Statement Analysis – Financial Results
- Gannett Co Inc (NWDVW) Income Statement Analysis – Financial Results
- Futura Medical plc (FUM.L) Income Statement Analysis – Financial Results
- CyberZONE, Inc. (CYZN) Income Statement Analysis – Financial Results
Cybertrust Japan Co., Ltd. (4498.T)
About Cybertrust Japan Co., Ltd.
Cybertrust Japan Co., Ltd. engages in the certification authority and security, IoT, and Linux/OSS businesses in Japan. It offers commercial digital authentication services covering SSL/TLS server certificate, client certificate, web security service, and vulnerability testing; secure IoT platform that allow users to manage the security status of IoT devices throughout their lifecycle from the semiconductor design to the disposal process stage; and Linux OS/integrated monitoring tool and backup software services. The company was founded in 2000 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.47B | 6.17B | 5.73B | 4.90B | 4.42B | 4.17B | 2.63B |
| Cost of Revenue | 3.41B | 3.28B | 3.17B | 2.73B | 2.40B | 2.15B | 1.23B |
| Gross Profit | 3.05B | 2.89B | 2.56B | 2.16B | 2.03B | 2.02B | 1.40B |
| Gross Profit Ratio | 47.20% | 46.80% | 44.73% | 44.15% | 45.83% | 48.45% | 53.35% |
| Research & Development | 40.00M | 36.00M | 0.00 | 0.00 | 0.00 | 2.60M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.59B | 1.03B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.90B | 1.83B | 1.69B | 1.59B | 1.49B | 1.59B | 1.03B |
| Other Expenses | 0.00 | 7.03M | -2.93M | 129.90M | 1.27M | 8.19M | -320.00K |
| Operating Expenses | 1.94B | 1.83B | 1.69B | 1.59B | 1.49B | 1.59B | 1.03B |
| Cost & Expenses | 5.35B | 5.11B | 4.86B | 4.32B | 3.88B | 3.74B | 2.26B |
| Interest Income | 53.00K | 66.00K | 126.00K | 175.00K | 206.00K | 248.00K | 206.00K |
| Interest Expense | 802.00K | 1.14M | 1.49M | 1.86M | 2.32M | 1.56M | 170.00K |
| Depreciation & Amortization | 604.09M | 570.16M | 515.62M | 373.85M | 303.65M | 313.96M | 172.39M |
| EBITDA | 1.38B | 1.64B | 1.31B | 1.01B | 827.69M | 633.90M | 529.73M |
| EBITDA Ratio | 21.38% | 26.56% | 24.22% | 22.30% | 19.03% | 17.99% | 20.60% |
| Operating Income | 1.11B | 1.05B | 868.79M | 574.18M | 537.19M | 430.75M | 371.00M |
| Operating Income Ratio | 17.20% | 17.08% | 15.16% | 11.73% | 12.15% | 10.33% | 14.10% |
| Total Other Income/Expenses | -336.04M | 11.85M | -71.00M | 56.22M | -15.47M | -112.37M | -13.84M |
| Income Before Tax | 776.15M | 1.07B | 797.79M | 630.39M | 521.72M | 318.38M | 357.16M |
| Income Before Tax Ratio | 12.00% | 17.28% | 13.92% | 12.88% | 11.80% | 7.64% | 13.57% |
| Income Tax Expense | 257.33M | 340.43M | 267.52M | 221.51M | 170.97M | 110.63M | 81.20M |
| Net Income | 518.82M | 725.16M | 530.27M | 408.88M | 350.75M | 207.75M | 275.96M |
| Net Income Ratio | 8.02% | 11.76% | 9.25% | 8.35% | 7.93% | 4.98% | 10.49% |
| EPS | 64.26 | 90.40 | 66.74 | 52.28 | 44.85 | 28.67 | 36.21 |
| EPS Diluted | 60.15 | 84.41 | 61.68 | 52.28 | 44.85 | 27.26 | 36.21 |
| Weighted Avg Shares Out | 8.07M | 8.02M | 7.95M | 7.82M | 7.82M | 7.25M | 7.62M |
| Weighted Avg Shares Out (Dil) | 8.63M | 8.59M | 8.60M | 7.82M | 7.82M | 7.62M | 7.62M |
TuxCare Announces Strategic Partnership with Cybertrust Japan to Support Country’s AlmaLinux Users
PALO ALTO, Calif.--(BUSINESS WIRE)--TuxCare, the enterprise solutions division of CloudLinux, today announced a strategic partnership with Tokyo-based Cybertrust Japan Co., Ltd. (TYO: 4498), a subsidiary of Softbank Technology Corp. Through the collaboration, Cybertrust Japan becomes the region’s exclusive reseller of...
Six Nuveen Closed-End Funds Declare Distributions
NEW YORK--(BUSINESS WIRE)--Nuveen Core Equity Alpha Fund (JCE), Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX), Nuveen S&P 500 Dynamic Overwrite Fund (SPXX), Nuveen Dow 30SM Dynamic Overwrite Fund (DIAX), Nuveen S&P 500 Buy-Write Income Fund (BXMX) and Nuveen Real Estate...
Six Nuveen Closed-End Funds Announce Availability of 19(a) Notices
NEW YORK--(BUSINESS WIRE)--The 19(a) quarterly distribution notices for six Nuveen closed-end funds are now available. These informational notices provide further details on the sources of the funds’ quarterly distributions and follows the most recent quarterly distribution announcements. The full text...
Form 8.3 - Takeda Pharmaceutical Company Limited
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION The naming of nominee or vehicle companies is...
Sprint Expands in Northern California with 43 New Retail Stores Creating More Than 300 Jobs
SAN FRANCISCO--(BUSINESS WIRE)--Sprint (NYSE:S) continues to expand its presence and investment in Northern California with plans to add more than 300 new jobs and 43 new retail locations throughout the area by the end of 2017. The new jobs will...
DARZALEX® (daratumumab) di Janssen è stato approvato come trattamento monoterapico dalla Commissione europea per il trattamento del mieloma multiplo (MM)
BEERSE, Belgio--(BUSINESS WIRE)-- Janssen-Cilag International NV (“Janssen”) ha annunciato in data odierna che la Commissione europea (CE) ha concesso l’approvazione condizionata di DARZALEX® (daratumumab) come monoterapia per pazienti adulti affetti da mieloma multiplo (MM) recidivato e refrattario, precedentemente sottoposti a...
DARZALEX® (Daratumumab)-Monotherapie von Janssen erhält Zulassung der Europäischen Kommission zur Behandlung des Multiplen Myeloms (MM)
BEERSE, Belgien--(BUSINESS WIRE)--Janssen-Cilag International NV („Janssen“) gab heute bekannt, dass die Europäische Kommission die bedingte Zulassung für DARZALEX® (Daratumumab) für die Monotherapie erwachsener Patienten mit rezidiviertem und refraktärem Multiplem Myelom (MM), bei deren vorangegangener Therapie Proteasominhibitoren (PI) und ein immunmodulatorischer...
Le DARZALEX® (daratumumab) de JANSSEN en monothérapie approuvé par la Commission européenne pour le traitement du myélome multiple (MM)
BEERSE, Belgique--(BUSINESS WIRE)-- Janssen-Cilag International NV (« Janssen ») a annoncé aujourd'hui que la Commission européenne (CE) avait accordé une approbation conditionnelle au DARZALEX® (daratumumab) en monothérapie pour les patients adultes atteints de myélome multiple (MM) récurrent et réfractaire, ayant...
Janssen’s Single-Agent DARZALEX® (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)
BEERSE, Belgium--(BUSINESS WIRE)-- Janssen-Cilag International NV (“Janssen”) today announced that the European Commission (EC) has granted conditional approval to DARZALEX® (daratumumab) for monotherapy of adult patients with relapsed and refractory multiple myeloma (MM), whose prior therapy included a proteasome inhibitor...
Source: https://incomestatements.info
Category: Stock Reports